DOXIL for Consolidation Therapy in Ovarian Cancer.
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The primary objective for this study is to evaluate the development, frequency and severity
of hand foot syndrome (HFS) in ovarian cancer subjects treated with Doxil®, as consolidation
therapy, on an every two week schedule.
The secondary objective for this study is to assess one-year progression free survival rate
(PFS).